These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 34476105)

  • 1. Improvement in recurring nivolumab-induced pneumonitis with repetitive administration of infliximab in a patient with head and neck cancer: A case report.
    Ueno S; Uenomachi M; Kusaba H; Ito M; Suzuki K; Ohmura H; Tsuchihashi K; Ariyama H; Akashi K; Baba E
    Mol Clin Oncol; 2021 Oct; 15(4):221. PubMed ID: 34476105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report.
    Li H; Ma W; Yoneda KY; Moore EH; Zhang Y; Pu LL; Frampton GM; Molmen M; Stephens PJ; Li T
    J Hematol Oncol; 2017 Feb; 10(1):64. PubMed ID: 28245875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High incidence and early onset of nivolumab-induced pneumonitis: four case reports and literature review.
    Koyama N; Iwase O; Nakashima E; Kishida K; Kondo T; Watanabe Y; Takahashi H; Umebayashi Y; Ogawa Y; Miura H
    BMC Pulm Med; 2018 Jan; 18(1):23. PubMed ID: 29378571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid temporal improvement of pembrolizumab-induced pneumonitis using the anti-TNF-α antibody infliximab.
    Sawai Y; Katsuya Y; Shinozaki-Ushiku A; Iwasaki A; Fukayama M; Watanabe K; Nagase T
    Drug Discov Ther; 2019 Jul; 13(3):164-167. PubMed ID: 31257354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Late-onset programmed cell death protein-1 inhibitor-induced pneumonitis after cessation of nivolumab or pembrolizumab in patients with advanced non-small cell lung cancer: a case series.
    Kimura H; Sone T; Araya T; Murata A; Yamamura K; Ohkura N; Hara J; Abo M; Kasahara K
    Transl Lung Cancer Res; 2021 Mar; 10(3):1576-1581. PubMed ID: 33889531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrent Episodes of Nivolumab-Induced Pneumonitis after Nivolumab Discontinuation and the Time Course of Carcinoembryonic Antigen Levels: A Case of a 58-Year-Old Woman with Non-Small Cell Lung Cancer.
    de Jong C; Peters BJM; Schramel FMNH
    Chemotherapy; 2018; 63(5):272-277. PubMed ID: 30572331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nivolumab for recurrent/metastatic hypopharyngeal squamous cell carcinoma in a liver transplant recipient.
    Kondo T; Kawachi S; Nakatsugawa M; Takeda A; Kikawada N; Aihara Y; Okimura A; Hirano H; Ogawa Y; Tsukahara K
    Auris Nasus Larynx; 2022 Aug; 49(4):721-726. PubMed ID: 33612350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiation recall pneumonitis induced by nivolumab in a patient with renal cell carcinoma.
    Nakamura K; Okubo K; Takahashi T; Mitsumori K; Ishigaki T; Ohnishi H
    IJU Case Rep; 2019 Jan; 2(1):30-33. PubMed ID: 32743367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nivolumab-related tracheobronchial chondritis: Extremely rare manifestation of an immune-related adverse effect.
    Kuba K; Nakahira M; Inoue H; Kogashiwa Y; Ebihara Y; Sugasawa M
    Head Neck; 2020 Nov; 42(11):E43-E48. PubMed ID: 32888225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid recovery of postnivolumab vemurafenib-induced Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome after tocilizumab and infliximab administration.
    Maximova N; Maestro A; Zanon D; Marcuzzi A
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32066648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immune-related pneumonitis caused by programmed death-1 inhibitor Pembrolizumab: a case report and literature review].
    Chen YL; Zhao J; Jia R; Wang HY; Zheng J; Bai CQ; Wang MZ; Xu JM
    Zhonghua Jie He He Hu Xi Za Zhi; 2017 Oct; 40(10):736-743. PubMed ID: 29050127
    [No Abstract]   [Full Text] [Related]  

  • 12. Nivolumab-induced pneumonitis and cardiopathy in a patient with relapsed Hodgkin's lymphoma.
    Bonhomme-Faivre L; Guarino V; Misra SC
    J Oncol Pharm Pract; 2023 Mar; 29(2):479-483. PubMed ID: 35658620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resolution of Infliximab-Refractory Nivolumab-Induced Acute Severe Enterocolitis After Cyclosporine Treatment in a Patient with Non-Small Cell Lung Cancer.
    Iyoda T; Kurita N; Takada A; Watanabe H; Ando M
    Am J Case Rep; 2018 Mar; 19():360-364. PubMed ID: 29581417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nivolumab-Induced, Late-Onset, Steroid-Sensitive, High-Grade Pneumonitis and Durable Tumor Suppression in Metastatic Renal Cell Carcinoma: A Case Report.
    Mendiola VL; Kesireddy M; Jana B
    Case Rep Oncol Med; 2019; 2019():6759472. PubMed ID: 31949965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness of Nivolumab in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma.
    Zargar M; McFarlane T; Chan KKW; Wong WWL
    Oncologist; 2018 Feb; 23(2):225-233. PubMed ID: 29021380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tracheobronchial chondritis as an immune-related adverse event occurring during the administration of nivolumab for recurrent hypopharyngeal squamous cell carcinoma.
    Someya M; Kondo T; Okimura A; Nakatsugawa M; Okubo M; Yunaiyama D; Takeda A; Kishida T; Yoshida S; Yonekura M; Ogawa Y; Tsukahara K
    Ear Nose Throat J; 2022 Mar; ():1455613221081912. PubMed ID: 35343278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapidly progressing programmed cell death 1 inhibitor-related pneumonitis in a hemodialytic patient with metastatic renal cell carcinoma.
    Matsumura Y; Iemura Y; Fukui S; Tatsumi Y; Kagebayashi Y; Samma S
    IJU Case Rep; 2019 May; 2(3):155-157. PubMed ID: 32743399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recurrent Pneumonitis in Patients with Melanoma Treated with Immune Checkpoint Inhibitors.
    Asher N; Marom EM; Ben-Betzalel G; Baruch EN; Steinberg-Silman Y; Schachter J; Shapira-Frommer R; Markel G
    Oncologist; 2019 May; 24(5):640-647. PubMed ID: 30777894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Successful Treatment of Squamous Cell Lung Cancer without PD-L1 Expression Using Fourth-Line Nivolumab].
    Ozawa R; Kuraishi H; Hirota S; Yamamoto M; Masubuchi T; Koyama S; Watanabe M
    Gan To Kagaku Ryoho; 2019 May; 46(5):917-920. PubMed ID: 31189815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two Cases of Nivolumab Re-Administration after Pneumonitis as Immune-Related Adverse Events.
    Imafuku K; Yoshino K; Yamaguchi K; Tsuboi S; Ohara K; Hata H
    Case Rep Oncol; 2017; 10(1):296-300. PubMed ID: 28512413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.